Stock Analysis, Dividends, Split History

JYNT / The Joint Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)118.32
Enterprise Value ($M)113.84
Book Value ($M)1.35
Book Value / Share0.10
Price / Book87.95
NCAV ($M)-10.21
NCAV / Share-0.74
Price / NCAV-11.58
Share Statistics
Common Stock Shares Outstanding 13,586,254
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 13,586,254
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.66
Return on Assets (ROA)-0.19
Return on Equity (ROE)-0.47
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.30
Income Statement (mra) ($M)
Technology Services Revenue1,137,363.00
Regional Developer Fees Revenue583,550.00
Franchise Revenue1,442,415.00
Other Sales Revenue Net11,125,115.00
Royalty Revenue7,722,856.00
Advertising Revenue2,753,776.00
Operating Income-3.17
Net Income-3.28
Earnings Per Share Basic And Diluted-0.25
Cash Flow Statement (mra) ($M)
Cash From Operations0.16
Cash from Investing-0.37
Cash from Financing-0.37
Identifiers and Descriptors
Central Index Key (CIK)1612630

Split History

Stock splits are used by The Joint Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

The Joint Offers Pain Relief For Your Back And Portfolio

2018-08-15 seekingalpha
The Joint has a high quality business model focused on growing their brand through franchises and then reacquiring or building stores to be run by corporate in already developed markets. This allows them to collect higher profits in areas where a customer base has already been established. The company has first mover advantage in creating a franchised brand in an historically fragmented sector. The current CEO has over 30 years of experience in building and growing franchised businesses. (2-0)

The Joint Corp. (JYNT) CEO Peter Holt on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
The Joint Corp. (NASDAQ:JYNT) Q2 2018 Results Earnings Conference Call August 9, 2018 5:00 PM ET (2-0)

The Joint Corp. 2018 Q2 - Results - Earnings Call Slides

2018-08-12 seekingalpha
The following slide deck was published by The Joint Corp. in conjunction with their 2018 Q2 earnings call. (2-0)

All It Was Cracked Up To Be... – ValueWalk Premium

2018-06-26 valuewalkpremium
One of the toughest decisions when investing in growth companies; is when to sell the winners. The issue is that successful businesses continue to increase in value over time. Therefore, selling means that you miss out on some of that growth. That said; I tend to find that despite having a multi-year forward valuation target, sometimes, a good chunk of that valuation gets realized in a much shorter time-frame. (1-0)

The Joint: Steady Growth In A Large, Fragmented Market

2018-06-06 seekingalpha
The market is just beginning to notice the growth. We believe this is an excellent speculative investment opportunity with the potential for serious, long-term returns. (1-0)

CUSIP: 47973J102